Echo Therapeutics, Inc. - FORM 10-K - EX-23.1 - CONSENT OF BDO USA LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM. - April 15, 2015

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.Financial_Report.xls
EX-32.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF - Echo Therapeutics, Inc.ex32-2.htm
EX-32.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT - Echo Therapeutics, Inc.ex32-1.htm
EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13A-14 (A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED - Echo Therapeutics, Inc.ex31-1.htm
EX-23.2 - CONSENT OF WOLF & COMPANY, P.C., INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM. - Echo Therapeutics, Inc.ex23-2.htm
EX-21.1 - SUBSIDIARIES OF THE COMPANY. - Echo Therapeutics, Inc.ex21-1.htm
EX-10.43 - AMENDMENT TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN ECHO THERAPEUTICS, INC. AND MEDICAL TECHNOLOGIES - Echo Therapeutics, Inc.ex10-43.htm
EX-10.39 - LETTER OF AGREEMENT - Echo Therapeutics, Inc.ex10-39.htm
EX-10.40 - SECURITIES PURCHASE AGREEMENT DATED DECEMBER 18, 2014, BY AND BETWEEN THE COMPANY, PLATINUM PARTNERS VALUE ARBITRAGE FUND L.P., BEIJING - Echo Therapeutics, Inc.ex10-40.htm
10-K - FORM 10K - Echo Therapeutics, Inc.ecte10k_12312014.htm
EX-31.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13A-14 (A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED - Echo Therapeutics, Inc.ex31-2.htm
Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 We hereby consent to the incorporation by reference in the Registration Statements (Nos. 333-164510, 333-152138, 333-92414, 333-101517, 333-106201, 333-122893, 333-134674, 333-143145 and 333-146607) on Form S-8 and Registration Statement (No. 333-175938) of Echo Therapeutics, Inc., on Form S-3 of our report dated April15, 2015, relating to the consolidated financial statements  which appear in the Annual Report on Form 10-K for the year ended December 31, 2014.  Our report contains an explanatory paragraph regarding the Company's ability to continue as a going concern. 

/s/ BDO USA, LLP
Woodbridge, New Jersey
April 15, 2015

Echo Therapeutics, Inc. Reports

Also read